Adoptive cellular therapy: A race to the finish line
- 25 March 2015
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 7 (280) , 280ps7
Abstract
Engineered T cells are under development in academic-industry partnerships, accelerating the pace toward widespread availability.Keywords
Funding Information
- EU FP7 (ATECT, SUPERSIST)
- K. G. Jebsen Center for Cancer Immunotherapy
This publication has 55 references indexed in Scilit:
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine, 2012
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine, 2012
- IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumorsJournal of Clinical Investigation, 2011
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cellsBlood, 2011
- T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient ColitisMolecular Therapy, 2011
- Development of Human Anti-Murine T-Cell Receptor Antibodies in Both Responding and Nonresponding Patients Enrolled in TCR Gene Therapy TrialsClinical Cancer Research, 2010
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine, 2010
- T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor modelBlood, 2009
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006